Display options
Cite
Colmenero J, Tabrizian P, Bhangui P, et al. De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management-Guidelines From the ILTS-SETH Consensus Conference. Transplantation. 2022;106(1):e30-e45doi: 10.1097/TP.0000000000003998.
Colmenero, J., Tabrizian, P., Bhangui, P., Pinato, D. J., Rodríguez-Perálvarez, M. L., Sapisochin, G., Bhoori, S., Pascual, S., Senzolo, M., Al-Adra, D., Herrero, J. I., Petrowsky, H., Dawson, L. A., Hosni, A., Kutzke, J. L., Gastaca, M., & Watt, K. D. (2022). De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management-Guidelines From the ILTS-SETH Consensus Conference. Transplantation, 106(1), e30-e45. https://doi.org/10.1097/TP.0000000000003998
Colmenero, Jordi, et al. "De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management-Guidelines From the ILTS-SETH Consensus Conference." Transplantation vol. 106,1 (2022): e30-e45. doi: https://doi.org/10.1097/TP.0000000000003998
Colmenero J, Tabrizian P, Bhangui P, Pinato DJ, Rodríguez-Perálvarez ML, Sapisochin G, Bhoori S, Pascual S, Senzolo M, Al-Adra D, Herrero JI, Petrowsky H, Dawson LA, Hosni A, Kutzke JL, Gastaca M, Watt KD. De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management-Guidelines From the ILTS-SETH Consensus Conference. Transplantation. 2022 Jan 01;106(1):e30-e45. doi: 10.1097/TP.0000000000003998. PMID: 34905760.
Copy Download .nbib Format: NLM
Share it on

Transplantation. 2022 Jan 01;106(1):e30-e45. doi: 10.1097/TP.0000000000003998.

De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management-Guidelines From the ILTS-SETH Consensus Conference.

Transplantation

Jordi Colmenero, Parissa Tabrizian, Prashant Bhangui, David James Pinato, Manuel L Rodríguez-Perálvarez, Gonzalo Sapisochin, Sherrie Bhoori, Sonia Pascual, Marco Senzolo, David Al-Adra, J Ignacio Herrero, Henrik Petrowsky, Laura A Dawson, Ali Hosni, Jade L Kutzke, Mikel Gastaca, Kymberly D Watt

Affiliations

  1. Liver Transplantation, Liver Unit Hospital Clínic Barcelona, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.
  2. Icahn School of Medicine at Mount Sinai, New York City, NY.
  3. Institute of Liver Transplantation and Regenerative Medicine, Medanta-The Medicity, Delhi NCR, India.
  4. Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom.
  5. Department of Hepatology and Liver Transplantation, Hospital Universitario Reina Sofía, University of Córdoba, IMIBIC, CIBERehd, Córdoba, Spain.
  6. Multi-Organ Transplant Program, Toronto General Hospital, University of Toronto, ON, Canada.
  7. HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.
  8. Liver Unit, CIBERehd, ISABIAL, HGU Alicante, Alicante, Spain.
  9. Multivisceral Transplant Unit, University Hospital of Padua, Padua, Italy.
  10. University of Wisconsin School of Medicine and Public Health, Madison, WI.
  11. Liver Unit, Clinica Universidad de Navarra, IdiSNA, CIBERehd, Pamplona, Spain.
  12. Swiss HPB and Transplantation Center, Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.
  13. Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, ON, Canada.
  14. Department of Pharmacy, Mayo Clinic, Rochester, MN.
  15. Cruces University Hospital, Biocruces Bizkaia Health Research Institute, University of the Basque Country, Bilbao, Spain.
  16. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

PMID: 34905760 DOI: 10.1097/TP.0000000000003998

Abstract

De novo malignancies (DNMs) following liver transplantation (LT) have been reported as 1 of the major causes of late mortality, being the most common cause of death in the second decade after LT. The overall incidence of DNMs is reported to be in the range of 3.1% to 14.4%, and the incidence is 2- to 3-fold higher in transplant recipients than in age- and sex-matched healthy controls. Long-term immunosuppressive therapy, which is the key in maintaining host tolerance and achieving good long-term outcomes, is known to contribute to a higher risk of DNMs. However, the incidence and type of DNM also depends on different risk factors, including patient demographics, cause of the underlying chronic liver disease, behavior (smoking and alcohol abuse), and pre-existing premalignant conditions. The estimated standardized incidence ratio for different DNMs is also variable. The International Liver Transplantation Society-Spanish Society of Liver Transplantation Consensus Conference working group on DNM has summarized and discussed the current available literature on epidemiology, risk factors, management, and survival after DNMs. Recommendations for screening and surveillance for specific tumors, as well as immunosuppression and cancer-specific management in patients with DNM, are summarized.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Conflict of interest statement

The authors declare no funding or conflicts of interest.

References

  1. Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891–1901. - PubMed
  2. Collett D, Mumford L, Banner NR, et al. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010;10:1889–1896. - PubMed
  3. Chandok N, Watt KD. Burden of de novo malignancy in the liver transplant recipient. Liver Transpl. 2012;18:1277–1289. - PubMed
  4. Daniel KE, Eickhoff J, Lucey MR. Why do patients die after a liver transplantation? Clin Transplant. 2017;31:e12906 - PubMed
  5. Schlegel A, Foley DP, Savier E, et al. Recommendations for donor and recipient selection and risk prediction: working group report from the ILTS Consensus Conference in DCD liver transplantation. Transplantation. 2021;105:1892–1903. - PubMed
  6. Taborelli M, Piselli P, Ettorre GM, et al.; Italian Transplant and Cancer Cohort Study. Survival after the diagnosis of de novo malignancy in liver transplant recipients. Int J Cancer. 2019;144:232–239. - PubMed
  7. Jiang Y, Villeneuve PJ, Fenton SS, et al. Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl. 2008;14:1588–1597. - PubMed
  8. Sérée O, Altieri M, Guillaume E, et al. Longterm risk of solid organ de novo malignancies after liver transplantation: a French national study on 11,226 patients. Liver Transpl. 2018;24:1425–1436. - PubMed
  9. Zhou J, Hu Z, Zhang Q, et al. Spectrum of de novo cancers and predictors in liver transplantation: analysis of the Scientific Registry of Transplant Recipients Database. PLoS One. 2016;11:e0155179. - PubMed
  10. Piselli P, Verdirosi D, Cimaglia C, et al. Epidemiology of de novo malignancies after solid-organ transplantation: immunosuppression, infection and other risk factors. Best Pract Res Clin Obstet Gynaecol. 2014;28:1251–1265. - PubMed
  11. Tsai HI, Lee CW, Kuo CF, et al. De novo malignancy in organ transplant recipients in Taiwan: a nationwide cohort population study. Oncotarget. 2017;8:36685–36695. - PubMed
  12. Chen W, Zheng R, Zhang S, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25:10–21. - PubMed
  13. Wang SM, Lai MN, Wei A, et al. Increased risk of urinary tract cancer in ESRD patients associated with usage of Chinese herbal products suspected of containing aristolochic acid. PLoS One. 2014;9:e105218. - PubMed
  14. Park HW, Hwang S, Ahn CS, et al. De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry. Transplant Proc. 2012;44:802–805. - PubMed
  15. Funk-Debleds P, Ducroux E, Guillaud O, et al. Subsequent nonmelanoma skin cancers and impact of immunosuppression in liver transplant recipients. J Am Acad Dermatol. 2018;79:84–91. - PubMed
  16. Tran M, Sander M, Ravani P, et al. Incidence of melanoma in organ transplant recipients in Alberta, Canada. Clin Transplant. 2016;30:1271–1275. - PubMed
  17. Hogue L, Harvey VM. Basal cell carcinoma, squamous cell carcinoma, and cutaneous melanoma in skin of color patients. Dermatol Clin. 2019;37:519–526. - PubMed
  18. Menzies S, O’Leary E, Callaghan G, et al. Declining incidence of keratinocyte carcinoma in organ transplant recipients. Br J Dermatol. 2019;181:983–991. - PubMed
  19. Rademacher S, Seehofer D, Eurich D, et al. The 28-year incidence of de novo malignancies after liver transplantation: a single-center analysis of risk factors and mortality in 1616 patients. Liver Transpl. 2017;23:1404–1414. - PubMed
  20. Piselli P, Busnach G, Citterio F, et al.; Immunosuppression and Cancer Study Group. Risk of Kaposi sarcoma after solid-organ transplantation: multicenter study in 4,767 recipients in Italy, 1970–2006. Transplant Proc. 2009;41:1227–1230. - PubMed
  21. Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018;378:549–562. - PubMed
  22. Mumtaz K, Faisal N, Marquez M, et al. Post-transplant lymphoproliferative disorder in liver recipients: characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations. Can J Gastroenterol Hepatol. 2015;29:417–422. - PubMed
  23. Khedmat H, Taheri S. Early onset post transplantation lymphoproliferative disorders: analysis of international data from 5 studies. Ann Transplant. 2009;14:74–77. - PubMed
  24. Mouchli MA, Singh S, Loftus EV Jr, et al. Risk factors and outcomes of de novo cancers (excluding nonmelanoma skin cancer) after liver transplantation for primary sclerosing cholangitis. Transplantation. 2017;101:1859–1866. - PubMed
  25. Singh S, Edakkanambeth Varayil J, Loftus EV Jr, et al. Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl. 2013;19:1361–1369. - PubMed
  26. Nure E, Frongillo F, Lirosi MC, et al. Incidence of upper aerodigestive tract cancer after liver transplantation for alcoholic cirrhosis: a 10-year experience in an Italian center. Transplant Proc. 2013;45:2733–2735. - PubMed
  27. Singh A, De A, Singh V. Post-transplant malignancies in alcoholic liver disease. Transl Gastroenterol Hepatol. 2020;5:30. - PubMed
  28. Engels EA. Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer. Am J Transplant. 2019;19:3223–3232. - PubMed
  29. Watt KD, Pedersen RA, Kremers WK, et al. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology. 2009;137:2010–2017. - PubMed
  30. Tiwari A, Saigal S, Choudhary NS, et al. De Novo malignancy after living donor liver transplantation: a large volume experience. J Clin Exp Hepatol. 2020;10:448–452. - PubMed
  31. Miao Y, Everly JJ, Gross TG, et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation. 2009;87:1347–1359. - PubMed
  32. Acuna SA, Fernandes KA, Daly C, et al. Cancer mortality among recipients of solid-organ transplantation in Ontario, Canada. JAMA Oncol. 2016;2:463–469. - PubMed
  33. Na R, Grulich AE, Meagher NS, et al. De novo cancer-related death in Australian liver and cardiothoracic transplant recipients. Am J Transplant. 2013;13:1296–1304. - PubMed
  34. Prenner S, Levitsky J. Comprehensive review on colorectal cancer and transplant. Am J Transplant. 2017;17:2761–2774. - PubMed
  35. Ajithkumar TV, Parkinson CA, Butler A, et al. Management of solid tumours in organ-transplant recipients. Lancet Oncol. 2007;8:921–932. - PubMed
  36. Rousseau B, Guillemin A, Tournigand C. Guidelines and tumor boards are required for solid organ recipients with de novo carcinoma. Oncotarget. 2019;10:2789–2790. - PubMed
  37. Chakkera HA, Mandarino LJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation. 2013;95:647–652. - PubMed
  38. Chak E, Saab S. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int. 2010;30:1247–1258. - PubMed
  39. Merchea A, Shahjehan F, Croome KP, et al. Colorectal cancer characteristics and outcomes after solid organ transplantation. J Oncol. 2019;2019:5796108. - PubMed
  40. van der Heide F, Dijkstra G, Porte RJ, et al. Smoking behavior in liver transplant recipients. Liver Transpl. 2009;15:648–655. - PubMed
  41. Herrero JI, España A, Quiroga J, et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl. 2005;11:1100–1106. - PubMed
  42. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681–1691. - PubMed
  43. Tunçer Vural A, Karataş Toğral A, Kirnap M, et al. Skin cancer risk awareness and sun-protective behavior among solid-organ transplant recipients. Exp Clin Transplant. 2018;16(Suppl 1):203–207. - PubMed
  44. Hernández-Sierra A, Rovira J, Petit A, et al. Role of HHV-8 and mTOR pathway in post-transplant Kaposi sarcoma staging. Transpl Int. 2016;29:1008–1016. - PubMed
  45. Jiménez-Romero C, Justo-Alonso I, Cambra-Molero F, et al. Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis. World J Hepatol. 2015;7:942–953. - PubMed
  46. Marroni CA, Fleck AM Jr, Fernandes SA, et al. Liver transplantation and alcoholic liver disease: history, controversies, and considerations. World J Gastroenterol. 2018;24:2785–2805. - PubMed
  47. Herrero JI, Pardo F, D’Avola D, et al. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal. Liver Transpl. 2011;17:402–408. - PubMed
  48. Mangus RS, Fridell JA, Kubal CA, et al. Worse long-term patient survival and higher cancer rates in liver transplant recipients with a history of smoking. Transplantation. 2015;99:1862–1868. - PubMed
  49. Chen YC, Cheng CH, Wang YC, et al. Betel quid chewing leads to the development of unique de novo malignancies in liver transplant recipients, a retrospective single center study in Taiwan. Medicine (Baltimore). 2016;95:e4901. - PubMed
  50. Bhat M, Mara K, Dierkhising R, et al. Gender, race and disease etiology predict de novo malignancy risk after liver transplantation: insights for future individualized cancer screening guidance. Transplantation. 2019;103:91–100. - PubMed
  51. Herrero JI, Lorenzo M, Quiroga J, et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl. 2005;11:89–97. - PubMed
  52. Cuadrado A, Fábrega E, Casafont F, et al. Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl. 2005;11:420–426. - PubMed
  53. Pearson-Stuttard J, Zhou B, Kontis V, et al. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018;6:e6–e15. - PubMed
  54. Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014;384:755–765. - PubMed
  55. Schauer DP, Feigelson HS, Koebnick C, et al. Bariatric surgery and the risk of cancer in a large multisite cohort. Ann Surg. 2019;269:95–101. - PubMed
  56. Matthews CE, Moore SC, Arem H, et al. Amount and intensity of leisure-time physical activity and lower cancer risk. J Clin Oncol. 2020;38:686–697. - PubMed
  57. Schmitz KH, Campbell AM, Stuiver MM, et al. Exercise is medicine in oncology: engaging clinicians to help patients move through cancer. CA Cancer J Clin. 2019;69:468–484. - PubMed
  58. Lee MS, Hsu CC, Wahlqvist ML, et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011;11:20. - PubMed
  59. Ma S, Zheng Y, Xiao Y, et al. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine (Baltimore). 2017;96:e6888. - PubMed
  60. Cardwell CR, Hicks BM, Hughes C, et al. Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol. 2014;32:3177–3183. - PubMed
  61. Demierre MF, Higgins PD, Gruber SB, et al. Statins and cancer prevention. Nat Rev Cancer. 2005;5:930–942. - PubMed
  62. Singh S, Singh PP. Statins for prevention of hepatocellular cancer: one step closer? Hepatology. 2014;59:724–726. - PubMed
  63. Vallakati A, Reddy S, Dunlap ME, et al. Impact of statin use after heart transplantation: a meta-analysis. Circ Heart Fail. 2016;9:e003265. - PubMed
  64. Qiao Y, Yang T, Gan Y, et al. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer. 2018;18:288. - PubMed
  65. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741–1750. - PubMed
  66. Wong G, Howard K, Craig JC, et al. Cost-effectiveness of colorectal cancer screening in renal transplant recipients. Transplantation. 2008;85:532–541. - PubMed
  67. Wong G, Howard K, Webster A, et al. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients. Transplantation. 2009;87:1078–1091. - PubMed
  68. Åberg F, Gissler M, Karlsen TH, et al. Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study. Hepatology. 2015;61:668–677. - PubMed
  69. Shalaby S, Burra P. De novo and recurrent malignancy. Best Pract Res Clin Gastroenterol. 2020;46-47:101680. - PubMed
  70. Stasko T, Brown MD, Carucci JA, et al.; International Transplant-Skin Cancer Collaborative; European Skin Care in Organ Transplant Patients Network. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg. 2004;30:642–650. - PubMed
  71. Zwald FO, Christenson LJ, Billingsley EM, et al.; Melanoma Working Group of The International Transplant Skin Cancer Collaborative and Skin Care in Organ Transplant Patients, Europe. Melanoma in solid organ transplant recipients. Am J Transplant. 2010;10:1297–1304. - PubMed
  72. Papier K, Gordon LG, Khosrotehrani K, et al. Management of organ transplant recipients attending a high-throughput skin cancer surgery and surveillance clinic in Queensland. Br J Dermatol. 2019;180:631–636. - PubMed
  73. Dharnidharka VR, Lamb KE, Gregg JA, et al. Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States. Am J Transplant. 2012;12:976–983. - PubMed
  74. Kerkar N, Morotti RA, Madan RP, et al. The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. Pediatr Transplant. 2010;14:504–511. - PubMed
  75. Allen UD, Preiksaitis JK; AST Infectious Diseases Community of Practice. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13652. - PubMed
  76. Oudkerk M, Liu S, Heuvelmans MA, et al. Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives. Nat Rev Clin Oncol. 2021;18:135–151. - PubMed
  77. Herrero JI, Bastarrika G, D’Avola D, et al. Lung cancer screening with low-radiation dose computed tomography after liver transplantation. Ann Transplant. 2013;18:587–592. - PubMed
  78. Renaud L, Hilleret MN, Thimonier E, et al. De novo malignancies screening after liver transplantation for alcoholic liver disease: a comparative opportunistic study. Liver Transpl. 2018;24:1690–1698. - PubMed
  79. Grossman DC, Curry SJ, Owens DK, et al.; US Preventive Services Task Force. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319:1901–1913. - PubMed
  80. Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol. 2017;18:e754–e766. - PubMed
  81. Liu Q, Yan L, Xu C, et al. Increased incidence of head and neck cancer in liver transplant recipients: a meta-analysis. BMC Cancer. 2014;14:776. - PubMed
  82. Presser SJ, Schumacher G, Neuhaus R, et al. De novo esophageal neoplasia after liver transplantation. Liver Transpl. 2007;13:443–450. - PubMed
  83. Chow LQM. Head and neck cancer. N Engl J Med. 2020;382:60–72. - PubMed
  84. European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation. J Hepatol. 2016;64:433–485. - PubMed
  85. Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol. 2021;116:458–479. - PubMed
  86. Zhang C, Cifu AS, Patel A. Recommendations for follow-up colonoscopy after polypectomy. JAMA. 2020;324:2208–2209. - PubMed
  87. Safaeian M, Robbins HA, Berndt SI, et al. Risk of colorectal cancer after solid organ transplantation in the United States. Am J Transplant. 2016;16:960–967. - PubMed
  88. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011;54:1842–1852. - PubMed
  89. Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect Med. 2013;3:a015677. - PubMed
  90. Komaki Y, Komaki F, Micic D, et al. Risk of colorectal cancer in chronic liver diseases: a systematic review and meta-analysis. Gastrointest Endosc. 2017;86:93–104.e5. - PubMed
  91. Rompianesi G, Ravikumar R, Jose S, et al. Incidence and outcome of colorectal cancer in liver transplant recipients: a national, multicentre analysis on 8115 patients. Liver Int. 2019;39:353–360. - PubMed
  92. Nasser-Ghodsi N, Mara K, Watt KD. De novo colorectal and pancreatic cancer in liver-transplant recipients: identifying the higher-risk populations. Hepatology. 2021;74:1003–1013. - PubMed
  93. Liauw SL, Ham SA, Das LC, et al. Prostate cancer outcomes following solid-organ transplantation: a SEER-Medicare analysis. J Natl Cancer Inst. 2020;112:847–854. - PubMed
  94. Steiner H, Bergmeister M, Verdorfer I, et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int. 2008;102:291–296. - PubMed
  95. Chien CS, Luo HL, Ling CS, et al. Upper urinary tract urothelial carcinoma behaviors in patients with end-stage renal disease after kidney transplantation in Taiwan. Int Urol Nephrol. 2016;48:1261–1265. - PubMed
  96. Kälble T, Lucan M, Nicita G, et al.; European Association of Urology. EAU guidelines on renal transplantation. Eur Urol. 2005;47:156–166. - PubMed
  97. Schünemann HJ, Lerda D, Quinn C, et al.; European Commission Initiative on Breast Cancer (ECIBC) Contributor Group. Breast cancer screening and diagnosis: a synopsis of the European breast guidelines. Ann Intern Med. 2020;172:46–56. - PubMed
  98. Liao JB, Fisher CE, Madeleine MM. Gynecologic cancers and solid organ transplantation. Am J Transplant. 2019;19:1266–1277. - PubMed
  99. Moscicki AB, Flowers L, Huchko MJ, et al. Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis. 2019;23:87–101. - PubMed
  100. Acuna SA, Huang JW, Scott AL, et al. Cancer screening recommendations for solid organ transplant recipients: a systematic review of clinical practice guidelines. Am J Transplant. 2017;17:103–114. - PubMed
  101. Finkenstedt A, Graziadei IW, Oberaigner W, et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant. 2009;9:2355–2361. - PubMed
  102. Herrero JI, Alegre F, Quiroga J, et al. Usefulness of a program of neoplasia surveillance in liver transplantation. a preliminary report. Clin Transplant. 2009;23:532–536. - PubMed
  103. Rodríguez-Perálvarez M, De la Mata M, Burroughs AK. Liver transplantation: immunosuppression and oncology. Curr Opin Organ Transplant. 2014;19:253–260. - PubMed
  104. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67. - PubMed
  105. Tjon AS, Sint Nicolaas J, Kwekkeboom J, et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl. 2010;16:837–846. - PubMed
  106. Wimmer CD, Angele MK, Schwarz B, et al. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients. Transpl Int. 2013;26:999–1006. - PubMed
  107. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351:623–628. - PubMed
  108. Lichtenberg S, Rahamimov R, Green H, et al. The incidence of post-transplant cancer among kidney transplant recipients is associated with the level of tacrolimus exposure during the first year after transplantation. Eur J Clin Pharmacol. 2017;73:819–826. - PubMed
  109. Carenco C, Assenat E, Faure S, et al. Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship. Am J Transplant. 2015;15:678–686. - PubMed
  110. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013;59:1193–1199. - PubMed
  111. Brem R, Karran P. Multiple forms of DNA damage caused by UVA photoactivation of DNA 6-thioguanine. Photochem Photobiol. 2012;88:5–13. - PubMed
  112. Jiyad Z, Olsen CM, Burke MT, et al. Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis. Am J Transplant. 2016;16:3490–3503. - PubMed
  113. O’Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:1186–1191. - PubMed
  114. Robson R, Cecka JM, Opelz G, et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant. 2005;5:2954–2960. - PubMed
  115. Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 2005;80:1233–1243. - PubMed
  116. Knoll GA, Kokolo MB, Mallick R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ. 2014;349:g6679. - PubMed
  117. Rodríguez-Perálvarez M, Guerrero-Misas M, Thorburn D, et al. Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011639. - PubMed
  118. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:222–230. - PubMed
  119. Hall EC, Engels EA, Pfeiffer RM, et al. Association of antibody induction immunosuppression with cancer after kidney transplantation. Transplantation. 2015;99:1051–1057. - PubMed
  120. Euvrard S, Morelon E, Rostaing L, et al.; TUMORAPA Study Group. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367:329–339. - PubMed
  121. Dantal J, Morelon E, Rostaing L, et al.; TUMORAPA Study Group. Sirolimus for secondary prevention of skin cancer in kidney transplant recipients: 5-year results. J Clin Oncol. 2018;36:2612–2620. - PubMed
  122. Salgo R, Gossmann J, Schöfer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10:1385–1393. - PubMed
  123. Campbell SB, Walker R, Tai SS, et al. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant. 2012;12:1146–1156. - PubMed
  124. Abdelmalek MF, Humar A, Stickel F, et al.; Sirolimus Liver Conversion Trial Study Group. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant. 2012;12:694–705. - PubMed
  125. Charlton M, Levitsky J, Aqel B, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients. Transplantation. 2018;102:727–743. - PubMed
  126. Lebbe C, Garbe C, Stratigos AJ, et al.; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of Kaposi’s sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer. 2019;114:117–127. - PubMed
  127. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1317–1323. - PubMed
  128. Campistol JM, Cuervas-Mons V, Manito N, et al.; ATOS Working Group. New concepts and best practices for management of pre- and post-transplantation cancer. Transplant Rev (Orlando). 2012;26:261–279. - PubMed
  129. Cillo U, De Carlis L, Del Gaudio M, et al. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. Hepatol Int. 2020;14:930–943. - PubMed
  130. Cheung CY, Man Ma MK, Chak WL, et al. Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers. Oncotarget. 2017;8:44833–44841. - PubMed
  131. Hellström VC, Enström Y, von Zur-Mühlen B, et al. Malignancies in transplanted patients: multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study. Acta Oncol. 2016;55:774–781. - PubMed
  132. Rousseau B, Guillemin A, Duvoux C, et al. Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma. Int J Cancer. 2019;144:886–896. - PubMed
  133. Thimonier E, Guillaud O, Walter T, et al. Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease. Clin Transplant. 2014;28:1339–1348. - PubMed
  134. Bilbao I, Salcedo M, Gómez MA, et al.; EVEROLIVER Study Group. Renal function improvement in liver transplant recipients after early everolimus conversion: a clinical practice cohort study in Spain. Liver Transpl. 2015;21:1056–1065. - PubMed
  135. Jiménez-Romero C, Manrique A, Marqués E, et al. Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience. Hepatogastroenterology. 2011;58:115–121. - PubMed
  136. Schnitzbauer AA, Filmann N, Adam R, et al. mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors. Ann Surg. 2020;272:855–862. - PubMed
  137. Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100:116–125. - PubMed
  138. De Simone P, Precisi A, Petruccelli S, et al. The impact of everolimus on renal function in maintenance liver transplantation. Transplant Proc. 2009;41:1300–1302. - PubMed
  139. Campistol JM, Cockwell P, Diekmann F, et al. Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int. 2009;22:681–687. - PubMed
  140. Dutt SB, Gonzales J, Boyett M, et al. mTOR inhibition by everolimus does not impair closure of punch biopsy wounds in renal transplant patients. Transplant Direct. 2017;3:e147. - PubMed
  141. Dobrindt EM, Biebl M, Rademacher S, et al. De-novo upper gastrointestinal tract cancer after liver transplantation: a demographic report. Int J Organ Transplant Med. 2020;11:71–80. - PubMed
  142. Gong CS, Yoo MW, Kim BS, et al. De novo gastric cancer after liver transplantation. Ann Transplant. 2016;21:386–391. - PubMed
  143. Na S, Lee GH, Song JH, et al. Endoscopic resection of gastric neoplasm in solid-organ transplant recipients. Transplantation. 2014;97:781–787. - PubMed
  144. Nishihori T, Strazzabosco M, Saif MW. Incidence and management of colorectal cancer in liver transplant recipients. Clin Colorectal Cancer. 2008;7:260–266. - PubMed
  145. Albright JB, Bonatti H, Stauffer J, et al. Colorectal and anal neoplasms following liver transplantation. Colorectal Dis. 2010;12:657–666. - PubMed
  146. Aigner F, Boeckle E, Albright J, et al. Malignancies of the colorectum and anus in solid organ recipients. Transpl Int. 2007;20:497–504. - PubMed
  147. Corral JE, Croome KP, Keaveny AP, et al. A 3-decade analysis of pancreatic adenocarcinoma after solid organ transplant. Pancreas. 2021;50:54–63. - PubMed
  148. Sigel K, Veluswamy R, Krauskopf K, et al. Lung cancer prognosis in elderly solid organ transplant recipients. Transplantation. 2015;99:2181–2189. - PubMed
  149. Shoji F, Toyokawa G, Harada N, et al. Surgical treatment and outcome of patients with de novo lung cancer after liver transplantation. Anticancer Res. 2017;37:2619–2623. - PubMed
  150. Jiménez C, Manrique A, Marqués E, et al. Incidence and risk factors for the development of lung tumors after liver transplantation. Transpl Int. 2007;20:57–63. - PubMed
  151. Drevet G, Duruisseaux M, Maury JM, et al. Lung cancer surgical treatment after solid organ transplantation: a single center 30-year experience. Lung Cancer. 2020;139:55–59. - PubMed
  152. Kwak HY, Chae BJ, Bae JS, et al. Breast cancer after kidney transplantation: a single institution review. World J Surg Oncol. 2013;11:77. - PubMed
  153. Kato T, Kakuta Y, Yamanaka K, et al. Early diagnosis and treatment of breast cancer in Japanese kidney transplant recipients: a single center experience. Springerplus. 2015;4:196. - PubMed
  154. Koonce SL, Giles B, McLaughlin SA, et al. Breast reconstruction after solid organ transplant. Ann Plast Surg. 2015;75:343–347. - PubMed
  155. Coordes A, Albers AE, Lenarz M, et al. Incidence and long-term survival of patients with de novo head and neck carcinoma after liver transplantation. Head Neck. 2016;38:707–714. - PubMed
  156. Suson KD, Sausville JE, Sener A, et al. Native nephrectomy for renal cell carcinoma in transplant recipients. Transplantation. 2011;91:1376–1379. - PubMed
  157. Tillou X, Demailly M, Hakami F, et al. De novo renal carcinoma in renal transplant recipients: effect of early treatment. Transplant Proc. 2009;41:3314–3316. - PubMed
  158. Tillou X, Chiche L, Guleryuz K, et al. Prostate carcinoma in liver transplant recipients: think about it! Urol Oncol. 2015;33:265.e9–265.e13. - PubMed
  159. Thompson RH, Leibovich BC, Karnes RJ, et al. Radical retropubic prostatectomy in immunosuppressed transplant recipients. J Urol. 2008;179:1349–1352. Discussion 1352. - PubMed
  160. Hevia V, Boissier R, Rodríguez-Faba Ó, et al. Management of localised prostate cancer in kidney transplant patients: a systematic review from the EAU Guidelines on Renal Transplantation Panel. Eur Urol Focus. 2018;4:153–162. - PubMed
  161. Ladwa R, Kalas T, Pathmanathan S, et al. Maintaining dose intensity of adjuvant chemotherapy in older patients with breast cancer. Clin Breast Cancer. 2018;18:e1181–e1187. - PubMed
  162. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6:546–558. - PubMed
  163. Bhat M, Mara K, Dierkhising R, et al. Immunosuppression, race, and donor-related risk factors affect de novo cancer incidence across solid organ transplant recipients. Mayo Clin Proc. 2018;93:1236–1246. - PubMed
  164. Billups K, Neal J, Salyer J. Immunosuppressant-driven de novo malignant neoplasms after solid-organ transplant. Prog Transplant. 2015;25:182–188. - PubMed
  165. Anglicheau D, Legendre C, Beaune P, et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics. 2007;8:835–849. - PubMed
  166. Aapro MS, Bohlius J, Cameron DA, et al.; European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32. - PubMed
  167. Keizer RJ, Huitema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:493–507. - PubMed
  168. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:692–706. - PubMed
  169. Waghray A, Balci B, El-Gazzaz G, et al. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant. 2013;27:555–561. - PubMed
  170. Sposito C, Mariani L, Germini A, et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol. 2013;59:59–66. - PubMed
  171. Manohar S, Thongprayoon C, Cheungpasitporn W, et al. Systematic review of the safety of immune checkpoint inhibitors among kidney transplant patients. Kidney Int Rep. 2020;5:149–158. - PubMed
  172. DeLeon TT, Salomao MA, Aqel BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. J Gastrointest Oncol. 2018;9:1054–1062. - PubMed
  173. Murakami N, Mulvaney P, Danesh M, et al.; Immune Checkpoint Inhibitors in Solid Organ Transplant Consortium. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021;100:196–205. - PubMed
  174. Owoyemi I, Vaughan LE, Costello CM, et al. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: a single-center analysis. Cancer. 2020;126:4780–4787. - PubMed
  175. Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019;7:106. - PubMed
  176. Munker S, De Toni EN. Use of checkpoint inhibitors in liver transplant recipients. United European Gastroenterol J. 2018;6:970–973. - PubMed
  177. Peeraphatdit TB, Wang J, Odenwald MA, et al. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology. 2020;72:315–329. - PubMed
  178. Dougan M, Wang Y, Rubio-Tapia A, et al. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology. 2021;160:1384–1393. - PubMed
  179. Mazzola R, Cuccia F, Bertani A, et al. The role of radiotherapy in patients with solid tumours after solid organ transplantation: a systematic review. Lancet Oncol. 2021;22:e93–e104. - PubMed
  180. Miften M, Vinogradskiy Y, Moiseenko V, et al. Radiation dose-volume effects for liver SBRT. Int J Radiat Oncol Biol Phys. 2021;110:196–205. - PubMed
  181. Rim CH, Seong J. Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat Oncol J. 2016;34:160–167. - PubMed
  182. Lee S, Kim H, Ji Y, et al. Evaluation of hepatic toxicity after repeated stereotactic body radiation therapy for recurrent hepatocellular carcinoma using deformable image registration. Sci Rep. 2018;8:16224. - PubMed
  183. Huang WY, Jen YM, Lee MS, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;84:355–361. - PubMed
  184. Walburn T, Moon AM, Hayashi PH, et al. Stereotactic body radiation therapy for recurrent, isolated hepatocellular carcinoma lymph node metastasis with or without prior liver transplantation. Cureus. 2020;12:e9988. - PubMed
  185. Au KP, Chiang CL, Chan ACY, et al. Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation. World J Clin Cases. 2020;8:2758–2768. - PubMed

Publication Types